CSIMarket
 
Urogen Pharma Ltd   (URGN)
Other Ticker:  
 
 
Price: $12.2000 $-0.06 -0.489%
Day's High: $12.6631 Week Perf: 0.41 %
Day's Low: $ 12.07 30 Day Perf: -1.45 %
Volume (M): 603 52 Wk High: $ 20.70
Volume (M$): $ 7,358 52 Wk Avg: $14.59
Open: $12.33 52 Wk Low: $10.60



 Market Capitalization (Millions $) 449
 Shares Outstanding (Millions) 37
 Employees 129
 Revenues (TTM) (Millions $) 84
 Net Income (TTM) (Millions $) -114
 Cash Flow (TTM) (Millions $) 200
 Capital Exp. (TTM) (Millions $) 0

Urogen Pharma Ltd
Urogen Pharma Ltd is a pharmaceutical company that specializes in the development and commercialization of innovative therapies for urological and urogenital diseases. The company focuses on diseases such as bladder cancer, overactive bladder, and prostate cancer. Urogen Pharma aims to improve the quality of life for patients by providing effective and safe treatments. The company utilizes advanced technologies and research to develop novel drug candidates and therapies, with a focus on precision medicine and targeted therapies. Urogen Pharma is dedicated to addressing unmet medical needs in the urology field and improving patient outcomes.


   Company Address: 400 Alexander Park Drive Princeton 8540 NJ
   Company Phone Number: 768-9780   Stock Exchange / Ticker: NASDAQ URGN


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Business Update

Navigating the Financial Storm UroGen Pharmas Hopeful Path with FDA Nod for UGN-102

Published Wed, Oct 16 2024 3:12 AM UTC

In what may become a significant breakthrough in bladder cancer treatment, UroGen Pharma Ltd., the Princeton-based biopharmaceutical company, announced the U.S. Food and Drug Administration (FDA)'s acceptance of their New Drug Application (NDA) for UGN-102 (mitomycin) for intravesical solution. UGN-102, designed to treat low-grade intermediate-risk non-muscle invasive bladde...

Business Update

UroGen Pharmas UGN-102 A Potential Breakthrough in Treating Non-Muscle Invasive Bladder Cancer

Published Tue, Oct 15 2024 9:36 PM UTC

In a significant stride for both UroGen Pharma Ltd. and the realm of oncology, the company has announced the U.S. Food and Drug Administration?s (FDA) acceptance of its New Drug Application (NDA) for UGN-102, an investigational drug formulated as an intravesical solution containing mitomycin. This pivotal development presents an exciting opportunity for the treatment of low-...

Business Update

UroGen Pharma Advances Bladder Cancer Treatment First Patient Dosed in Phase 3 Trial of UGN-103

Published Wed, Oct 2 2024 12:47 PM UTC

In a significant milestone for bladder cancer treatment, UroGen Pharma Ltd. (Nasdaq: URGN) has announced the dosing of the first patient in its Phase 3 clinical trial for UGN-103, an innovative mitomycin-based formulation. This investigational drug is specifically tailored for the treatment of low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC), a ch...

Business Update

UroGen Pharma Seeks FDA Approval for UGN-102 A New Hope for Patients with Low-Grade Intermediate-Risk Non-Mus...

Published Wed, Aug 14 2024 12:47 PM UTC

In a landmark announcement, UroGen Pharma Ltd. (Nasdaq: URGN), a pioneering biopharmaceutical company focused on developing innovative therapies for urothelial and specialty cancers, has officially submitted a New Drug Application (NDA) for UGN-102 (mitomycin) for intravesical solution. This submission is a crucial milestone in the journey toward providing a new treatment op...

Stock Market Announcement

UroGen Pharma's Public Offering: Fueling Innovation in the Fight Against Urothelial and Specialty Cancers

Published Mon, Jun 17 2024 8:47 PM UTC

UroGen Pharma Announces Commencement of Public Offering: Assessing the Impact on Company Shares
UroGen Pharma Ltd., a biotech company focusing on innovative solutions for urothelial and specialty cancers, recently announced the commencement of an underwritten public offering. This offering allows UroGen to issue and sell its ordinary shares and pre-funded warrants to th...







Urogen Pharma Ltd's Segments





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com